UnknownPhase 2NCT01954693
A Study of Everolimus in the Treatment of Neurocognitive Problems in Tuberous Sclerosis
Studying Autosomal dominant polycystic kidney disease type 1 with tuberous sclerosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Cardiff University
- Principal Investigator
- Julian Sampson, ProfCardiff University
- Intervention
- Placebo(drug)
- Enrollment
- 48 enrolled
- Eligibility
- 16-60 years · All sexes
- Timeline
- 2012 – 2018
Study locations (1)
- Cardiff University, Cardiff, United Kingdom
Collaborators
Novartis
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01954693 on ClinicalTrials.govOther trials for Autosomal dominant polycystic kidney disease type 1 with tuberous sclerosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07561957A Smart Phone Application to Improve Adoption of the 2024 Kidney Disease Improving Global Outcomes (KDIGO) Chronic Kidney Disease (CKD) GuidelinesSt. James's Hospital, Ireland
- RECRUITINGPHASE1NCT07369505Sapu003 in Advanced mTOR-sensitive Solid TumorsSAPU NANO (US) LLC
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT06392009Astroscape: A Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients With TSC or FCD Type IIGRIN Therapeutics, Inc.
- ACTIVE NOT RECRUITINGNCT02461459Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC)Boston Children's Hospital
See all trials for Autosomal dominant polycystic kidney disease type 1 with tuberous sclerosis →